Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.44 |
| ▸ | TRPC7 | Q9HCX4 | 2/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.44 |
| ▸ | CDK2 | P24941 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12953929 | 0.91 | GSK3B (0.71) | GSK3BCCNE1CDK2 | |
| SCHEMBL14043203 | 0.89 | TRPC3 (0.44) | GSK3BGRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL13289048 | 0.88 | GSK3B (0.59) | GSK3BCHEK1CCNE1CDK2 | |
| SCHEMBL13288831 | 0.88 | GSK3B (0.59) | GSK3BCHEK1CCNE1CDK2 | |
| SCHEMBL12954326 | 0.87 | GSK3B (0.58) | GSK3BGRIN2BCHEK1CCNE1CDK2 | |
| SCHEMBL13288814 | 0.87 | GSK3B (0.61) | GSK3BCHEK1CCNE1CDK2 | |
| SCHEMBL12953848 | 0.87 | GSK3B (0.61) | GSK3BCHEK1CCNE1CDK2 | |
| SCHEMBL13305370 | 0.87 | GSK3B (0.61) | GSK3BCHEK1CCNE1CDK2 | |
| SCHEMBL13304833 | 0.86 | CA2 (0.52) | GSK3BGRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL12953065 | 0.85 | GSK3B (0.61) | GSK3BCHEK1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |